5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
NEUTRAL | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 4.42▼ | 4.32▲ | 4.25▲ | 3.79▲ | 3.28▲ |
MA10 | 4.49▼ | 4.17▲ | 4.07▲ | 3.65▲ | 3.24▲ |
MA20 | 4.39▼ | 4.02▲ | 3.87▲ | 3.20▲ | 3.71▲ |
MA50 | 4.19▲ | 3.77▲ | 3.66▲ | 3.20▲ | 5.04▼ |
MA100 | 4.02▲ | 3.66▲ | 3.37▲ | 3.68▲ | 5.50▼ |
MA200 | 3.83▲ | 3.32▲ | 3.12▲ | 4.66▼ | 8.42▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.022▼ | 0.040▲ | 0.062▲ | 0.122▲ | 0.147▲ |
RSI | 51.985▲ | 74.631▲ | 76.986▲ | 76.613▲ | 54.756▲ |
STOCH | 28.495 | 86.261▲ | 86.883▲ | 76.947 | 44.863 |
WILL %R | -74.419 | -37.209 | -28.444 | -14.953▲ | -13.531▲ |
CCI | -57.356 | 136.163▲ | 150.847▲ | 178.457▲ | 129.085▲ |
Thursday, May 01, 2025 10:55 AM
Discover Fulcrum Therapeutics' Q1 2025 progress in the PIONEER trial for sickle cell disease, financial insights, and upcoming data milestones.
|
Thursday, May 01, 2025 10:55 AM
Fulcrum Therapeutics, Inc. ( NASDAQ: FULC) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Alex Sapir – President and Chief Executive Officer Alan Musso – Chief Financial Officer Iain Fraser – ...
|
Thursday, May 01, 2025 04:00 AM
Enrollment complete in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); initiated the 20 mg dose cohort ― ― On track to provide clinical data from ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
01/05/25 | 3.82 | 4.68 | 3.82 | 4.36 | 892,645 |
30/04/25 | 3.61 | 3.91 | 3.55 | 3.85 | 557,900 |
29/04/25 | 3.54 | 3.735 | 3.53 | 3.65 | 270,487 |
28/04/25 | 3.53 | 3.63 | 3.45 | 3.57 | 153,200 |
25/04/25 | 3.50 | 3.53 | 3.385 | 3.53 | 231,900 |
24/04/25 | 3.61 | 3.619 | 3.435 | 3.51 | 215,400 |
23/04/25 | 3.84 | 3.87 | 3.50 | 3.59 | 705,629 |
22/04/25 | 3.47 | 3.87 | 3.47 | 3.65 | 582,117 |
21/04/25 | 3.25 | 3.565 | 3.17 | 3.46 | 369,600 |
17/04/25 | 3.05 | 3.32 | 3.05 | 3.29 | 350,300 |
|
|
||||
|
|
||||
|
|